奥马环素与左氧氟沙星治疗社区获得性肺炎的临床疗效比较

Comparative clinical efficacy of omadacycline versus levofloxacin in treating community-acquired pneumonia

摘要:

目的 比较奥马环素与左氧氟沙星治疗社区获得性肺炎（CAP）的临床疗效。方法 选取2020年4月—2023年7月黄山市人民医院收治的80例CAP患者，按照治疗方法分为对照组和观察组。两组根据病情均酌情给予退热、止咳、补液、调节电解质平衡等常规治疗，在此基础上，对照组38例采用左氧氟沙星，观察组42例采用奥马环素，两组均治疗7 d，比较两组的临床疗效。结果 两组治疗有效率的比较，差异无统计学意义（P >0.05）。两组肺啰音消退时间、咳嗽消退时间、发热消退时间比较，差异均无统计学意义（P >0.05）。治疗前与治疗7 d后，观察组CURB-65评分的差值低于对照组（P < 0.05）；观察组C反应蛋白（CRP）、降钙素原（PCT）、白细胞介素-6（IL-6）、白细胞计数（WBC）、中性粒细胞百分比（NE）差值均大于对照组（P <0.05）。两组不良反应发生率的比较，差异无统计学意义（P > 0.05）。结论 奥马环素与左氧氟沙星对CAP的疗效相当，均能作为CAP的替代治疗药物，但奥马环素在减轻患者病情严重程度，改善炎症水平方面效果更佳。

Abstract:

Objective To compare the clinical efficacy of omadacycline and levofloxacin in the treatment of community-acquired pneumonia (CAP).Methods Eighty CAP patients admitted to Huangshan City People's Hospital from April 2020 to July 2023 were divided into a control group (n = 38) and an observation group (n = 42). Both groups received conventional treatments (antipyretics, antitussives, fluid replacement, electrolyte balance adjustment) based on clinical status. The control group received levofloxacin, while the observation group received omadacycline, both for 7 days. Clinical efficacy were compared.Results No statistically significant differences were observed in overall efficacy (P > 0.05), symptom resolution times (P > 0.05), or adverse reaction rates (P > 0.05) between the two groups. The observation group showed a greater reduction in CURB-65 scores post-treatment compared to the control group (P < 0.05). Significant differences favoring omadacycline were observed in the magnitude of decreases in CRP, PCT, IL-6, WBC, and NE levels (P < 0.05).Conclusion Omadacycline demonstrates comparable efficacy to levofloxacin for CAP treatment but exhibits superior anti-inflammatory effects and greater reduction in disease severity.